University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that will fund trials of its first candidate.
HepaRegenix, a Germany-based liver disease medicine spinout of University Hospital Tübingen, completed a series B round today that exceeded €11m ($12.2m) with investors including multi-institute tech transfer company Ascenion.
Pharmaceutical firm Boehringer Ingelheim backed the round through its Venture Fund, investing alongside its peer Novo, public-private partnership High-Tech Gründerfonds (HTGF) and Coparion, an investment fund backed by the German government and the EU.
Founded in 2015, HepaRegenix is working on drugs for acute and chronic liver diseases which…
